74 Drugmakers Including BeiGene Host Institutional Research as Interim Reports Peak
As of August 10, 74 pharmaceutical companies including BeiGene and Zelgen Pharmaceuticals have hosted institutional research visits since July 1, with seven firms attracting more than 50 institutions and BeiGene drawing over 200. Seventeen listed drugmakers have disclosed semi-annual reports and more than 100 have issued earnings forecasts. Innovative drug products with business development agreements are entering overseas clinical trials and commercialization stages, with the 2026 ESMO annual meeting expected to release key data.
By August 10, the pharmaceutical industry has entered the peak period for semi-annual report disclosures, with institutional research activity rising markedly. Wind data show that 17 listed pharmaceutical companies have disclosed semi-annual reports, while more than 100 companies have released interim earnings forecasts. Between July 1 and August 10, 74 pharmaceutical companies including BeiGene and Zelgen Pharmaceuticals hosted institutional research visits, with seven companies attracting more than 50 institutions and BeiGene receiving over 200.
In the innovative drug segment, products that have secured business development (BD) partnerships are progressively entering overseas pivotal clinical trials, regulatory approval and commercialization, and revenue-sharing milestones. The 2026 European Society for Medical Oncology (ESMO) annual meeting will release important data, and related technological breakthroughs and partnership progress are drawing market attention.
Why this event matters
The event has a measured impact on 2 industrys. The strongest current signal is positive for Pharmaceuticals, with intensity 60/100 and 70% confidence over a short term horizon.
Pharmaceuticals
- Direction
- positive
- Intensity
- 60
- Confidence
- 70%
- Horizon
- Short term
Biotechnology
- Direction
- positive
- Intensity
- 60
- Confidence
- 70%
- Horizon
- Short term
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.